chevron_leftBack
As of 5 June 2026, Biofrontera AG has a market cap of $17.2M USD, ranking #38162 globally and #379 in Germany.
It ranks #3400 in the Healthcare sector, and #1123 in the Drug Manufacturers - General industry.
Key Stats
Market Cap
$17.2MUSD
14.83M EUR
Enterprise Value
$13.11MUSD
11.29M EUR
Revenue (TTM)
$15.3MUSD
13.19M EUR
EBITDA (TTM)
-$977.98KUSD
-842.0K EUR
Net Income (TTM)
-$4.6MUSD
-3.97M EUR
EBITDA Margin
-6.4%
Profit Margin
-30%
PS Ratio
1.1
PB Ratio
1.0
Company Profile
Country (HQ)
Sector
Healthcare
Industry
Drug Manufacturers - General
Employees
75
Founded
1997
Website
biofrontera.com
open_in_new
warningChart data may be delayed
| 1d | 1w | 1m | 3m | 6m | 1y |
|---|---|---|---|---|---|
| -0.8% | -3.2% | -4.3% | -2.4% | -8.6% | 3.8% |
News
Loading...
Markets
| Exchange | Ticker | Price |
|---|---|---|
|
B8FK
ISIN: DE000A4BGGM7
Shares Out.:
Shares Outstanding:
6.077M1
Shares Float:
5.555M2
TV:
TradingView:
SA:
Stock Analysis:
YF:
Yahoo Finance:
GF:
Google Finance:
BA:
Barron's:
MS:
Morningstar:
|
2.42 EUR | |
|
0DOL
ISIN: DE000A4BGGM7
|
2.48 EUR | |
|
B8FK
ISIN: DE000A4BGGM7
|
2.37 EUR |
1Market cap is calculated using shares outstanding.
2Float shares are publicly tradable shares, excluding insider-held stock.
About Biofrontera AG
Biofrontera AG, a biopharmaceutical company, engages in the research, development, and distribution of dermatological products in Germany, Spain, the United Kingdom, rest of Europe, the United States, and internationally. The company offers Ameluz and BF-RhodoLED lamp for the treatment of mild and moderate actinic keratoses on the face and scalp, field cancerization, and fatal squamous cell carcinoma. It also provides RhodoLED XL lamp for the treatment of multiple interspersed lesions; and Belixos, a cosmetic product for irritated and sensitive skin. The company has a license and supply agreement with Maruho Co., Ltd. Biofrontera AG was founded in 1997 and is headquartered in Leverkusen, Germany.
Similar Companies
| Name |
Market Cap (USD)
diff.
|
PE | Country |
|---|---|---|---|
XETRA: MRK
|
$56.2B
327K%
48.46B EUR
|
18.6
|
|
XETRA: BAYN
|
$41.73B
243K%
35.98B EUR
|
-
|
|
XETRA: DMP
|
$2.63B
15K%
2.27B EUR
|
18.6
|
|
NASDAQ: IMTX
|
$1.49B
9K%
|
-
|
|
XETRA: FYB
|
$369.37M
2K%
318.47M EUR
|
-
|
|
XETRA: HPHA
|
$154.11M
796%
132.87M EUR
|
-
|
| Name |
Market Cap (USD)
diff.
|
PE | Country |
|---|---|---|---|
NYSE: LLY
|
$761.68B
4M%
|
38.1
|
|
NYSE: JNJ
|
$547.28B
3M%
|
26.4
|
|
NYSE: ABBV
|
$360.63B
2M%
|
97.4
|
|
SIX: RO
|
$323.4B
2M%
256.25B CHF
|
19.9
|
|
LSE: AZN
|
$289.25B
2M%
215.59B GBP
|
27.6
|
|
SIX: NOVN
|
$276.26B
2M%
218.9B CHF
|
20.5
|
chevron_leftBack